Y-box-binding protein 1 promotes tumor progression and inhibits cisplatin chemosensitivity in esophageal squamous cell carcinoma

6Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Y-box-binding protein 1 (YB-1) has been identified as a pleotropic oncoprotein in multiple human malignancies and is involved in the regulation of various DNA/RNA-dependent events, including transcription and translation. However, little is known about expression pattern and underlying functions of YB-1 in esophageal squamous cell carcinoma (ESCC). In this study, we report that up-regulated YB-1 is closely correlated with TNM stage and tumor size in ESCC specimens and predicts a poor prognosis in ESCC patients. Genetic silencing of YB-1 inhibits cell proliferation and invasive potential by regulating its targeted genes associated with tumor growth and metastasis. In particular, we also show that silencing of YB-1 enhances chemotherapy-induced cytotoxicity in EC109 and TE-1 cells by targeting multidrug resistance 1 (MDR1). Our findings demonstrate the oncogenic roles of YB-1 in ESCC and support it as a target for ESCC therapy.

Cite

CITATION STYLE

APA

Xu, J., & Hu, Z. (2016). Y-box-binding protein 1 promotes tumor progression and inhibits cisplatin chemosensitivity in esophageal squamous cell carcinoma. Biomedicine and Pharmacotherapy, 79, 17–22. https://doi.org/10.1016/j.biopha.2016.01.037

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free